Dr. Matthew B Schabath is a Senior Member with joint appointments in the Departments of Cancer Epidemiology and Thoracic Oncology. Dr. Schabath has expertise in quantitative imaging/radiomics, molecular epidemiology, cardiovascular/cardiotoxicity epidemiology, and health disparities among LGBTQ/SGM populations. Dr. Schabath’s lab leads efforts to develop and validate biomarkers in the lung cancer care continuum including early detection, overtreatment, diagnosis, and treatment response. These biomarkers include quantitative image-based biomarkers (radiomics), germline genetics, circulating biomarkers, and tumor-based biomarkers. Dr. Schabath is one of the first epidemiologists in the world to conduct research on radionics and deploy artificial intelligence approaches and has extensive publication and funding track records in these domains. Based on his expertise in radionics research, Dr. Schabath has been funded by the Early Detection Research Network (EDRN), Quantitative Imaging Network (QIN), Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions (MCL), and the Florida Department of Health (DOH) Biomedical Research Program.